Use of β-adrenergic receptor blockers in blacks

Journal of Clinical Pharmacology

Volumn 36, Issue 10, 1996, Pages 867-873

  Prisant, L Michael ^a   Mensah, George A ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BISOPROLOL; CARTEOLOL; LABETALOL; METOPROLOL; NADOLOL; PENBUTOLOL; PINDOLOL; PROPRANOLOL; TIMOLOL;

ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; CARDIOSELECTIVITY; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG EFFICACY; DRUG RECEPTOR BINDING; ETHNIC GROUP; HUMAN; INTRINSIC SYMPATHOMIMETIC ACTIVITY; RACE DIFFERENCE; RECEPTOR BLOCKING; REVIEW;

EID: 0029852231     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1996.tb04752.x     Document Type: Review

References (34)

1. Berglund G, Sannerstedt R, Andersson O, Wedel H, Wilhelmsen L, Hansson L, et al: Coronary heart disease after treatment of hypertension. Lancet 1978; 1:1-5.
2. Olsson G, Tuomilehto J, Berglund G, Elmfeldt D, Warnold I, Barber H, et al: Primary prevention of sudden cardiovascular death in hypertensive patients: mortality results from the MAPHY Study. Am J Hypertens 1991; 4:151-158.
3. The Norwegian Multicenter Study Group: Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981; 304:801-807.
4. Hjalmarson Å, Elmfeldt D, Herlitz J, Homberg S, Málek I, Nyberg G, et al: Effect on mortality of metoprolol in acute myocardial infarction: a double-blind randomised trial. Lancet 1981; 2:823- 827.
5. Boissel J-P, Leizorovicz A, Picolet H, Peyrieux J-C: Secondary prevention after high-risk acute myocardial infarction with low- dose acebutolol. Am J Cardiol 1990; 66:251-260.
6. Haywood LJ: Coronary heart disease mortality/morbidity and risk in blacks. I. Clinical manifestations and diagnostic criteria: the experience with the Beta Blocker Heart Attack Trial. Am Heart J 1984; 108:787-793.
7. Prisant LM, Carr AA, Bottini PB, Solursh DS, Solursh LP: Sexual dysfunction with antihypertensive drugs. Arch Intern Med 1994; 154:730-736.
8. Prisant LM, Spruill WJ, Fincham JE, Wade WE, Carr AA, Adams M: Depression associated with antihypertensive drugs. J Fam Pract 1991; 33:481-485.
9. Croog SH, Kong BW, Levine S, Weir MR, Baume RM, Saunders E: Hypertensive black men and women: quality of life and effects of antihypertensive medications. Arch Intern Med 1990; 150:1733-1741.
10. Humphreys GS, Delvin DG: Ineffectiveness of propranolol in hypertensive Jamaicans. Br Med J 1968; 2:601-603.
11. Richardson DW, Freund J, Gear AS, Mauck HP, Preston LW: Effect of propranolol on elevated arterial blood pressure. Circulation 1968; 37:534-542.
12. Cubeddu LX, Aranda J, Singh B, Klein M, Brachfeld J, Freis E, et al: A comparison of verapamil and propranolol for the initial treatment of hypertension: racial differences in response. JAMA 1986; 256:2214-2221.
13. Veterans Administration Cooperative Study Group on Antihypertensive Agents: Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. I. Results of short-term titration with emphasis on racial differences in response. JAMA 1982; 248:1996-2003.
14. Veterans Administration Cooperative Study Group on Antihypertensive Agents: Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. II. Results of long-term therapy. JAMA 1982; 248:2004-2011.
15. Veterans Administration Cooperative Study Group on Antihypertensive Agents: Efficacy of nadolol alone and combined with bendroflumethiazide and hydralazine for systemic hypertension. Am J Cardiol 1983; 52:1230-1237.
16. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, et al: Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. N Engl J Med 1993; 328:914-921.
17. Seedat YK: Trial of atenolol and chlorthalidone for hypertension in black South Africans. Br Med J 1980; 281:1241-1243.
18. Saunders E, Weir MR, Kong BW, Hollifield J, Gray J, Vertes V, et al: A comparison of efficacy and safety of a β-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med 1990; 150:1707-1713.
19. Materson BJ, Reda DJ: Correction: single-drug therapy for hypertension in men. N Engl J Med 1994; 330:1689.
20. Prisant LM, Carr AA, Desnoyers M, Westcott RJ, Zinny MA, O'Donnell DM, et al: Multicenter evaluation of the hemodynamic effects of bisoprolol in patients with mild to moderate hypertension. J Clin Pharmacol 1990; 30:1096-1101.
21. Neutel JM, Smith DHG, Ram VS, Lefkowitz MP, Kazempour MK, Weber MA: Comparison of bisoprolol with atenolol for systemic hypertension in four population groups (young, old, black and nonblack) using ambulatory blood pressure monitoring. Am J Cardiol 1993; 72:41-46.
22. Frishman WH, Bryzinski BS, Coulson LR, De Quattro VL, Vlachakis ND, Mroczek WJ, et al: A multifactorial trial design to assess combination therapy in hypertension: treatment with bisoprolol and hydrochlorothiazide. Arch Intern Med 1994; 154:1461-1468.
23. Frishman WH, Burris JF, Mroczek WJ, Weir MR, Alemayehu D, Simon JS, et al: Firstline therapy option with low-dose bisoprolol fumarate and low-dose hydrochlorothiazide in patients with stage I and stage II systemic hypertension. J Clin Pharmacol 1995; 35:182-188.
24. Plotnick GD, Fisher ML, Wohl B, Hamilton JH, Hamilton BP: Improvement in depressed cardiac function in hypertensive patients during pindolol treatment. Am J Med 1984; 76:25-30.
25. Moser M, Lunn J: Comparative effects of pindolol and hydrochlorothiazide in black hypertensive patients. Angiology 1981; 32: 561-566.
26. Venter CP, Joubert PH, Venter HL, Muntingh GL, du Plooy WJ: Penbutolol in the treatment of mild to moderate essential hypertension in black South Africans. J Clin Pharmacol 1990; 30:533- 537.
27. Ohman KP, Asplund J, Landahl S, Liander B: Penbutolol (HOE 893d) in primary hypertension. Eur J Clin Pharmacol 1982; 22:95-99.
28. Boyles PW: Effects of age and race on clinical response to acebutolol in essential hypertension. Am Heart J 1985; 109:1184-1192.
29. Abengowe CU: A double-blind comparison of acebutolol (Sectral) and propranolol (Inderal) in the treatment of hypertension in black Nigerian patients. J Int Med Res 1985; 13:116-121.
30. Flamenbaum W, Weber MA, McMahon FG, Materson BJ, Carr AA, Poland M: Monotherapy with labetalol compared with propranolol: differential effects by race. J Clin Hypertens 1985; 1:56- 69.
31. Cubberly RB: Labetalol as monotherapy in hypertensive black patients. J Clin Hypertens 1985; 4:304-314.
32. Saunders E, Curry C, Hinds J, Kong BW, Medakovic M, Poland M, Roper K: Labetalol compared with propranolol in the treatment of black hypertensives. J Clin Hypertens 1987; 3:294-302.
33. 1-selective blockade in essential hypertension in black and white patients. Clin Pharmacol Ther 1990; 48:665-675.
34. Wright JT, DiPette DJ, Goodman RP, Townsend R, McKenney JM: Renin profile, race, and antihypertensive efficacy with atenolol and labetalol. J Human Hypertens 1991; 5:193-198.